13F Holdings
中文EN

MBIO MUSTANG BIO, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1680048 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-51.1%
TTM EPS YoY92.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-43.1%
ROA-20.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets55.1%
Debt / equity0.00x
Current ratio—
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.29x
Accruals ratio6.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense—$7.56M$40.51M$62.48M$49.86M
SG&A expense$3.95M$4.13M$9.69M$12.21M$11.02M
Operating income-$2.43M-$16.25M-$49.26M-$76.16M-$66.72M
Interest expense—$5,000$4.11M$3.36M$15,000
Pretax income-$1.92M-$15.75M———
Income tax$27,000————
Net income-$1.92M-$15.75M-$51.60M-$77.53M-$66.37M
EBITDA-$2.40M-$15.57M-$47.40M-$73.44M-$64.56M
EPS (basic)-0.39-38.57-299.95-10.09-0.76
EPS (diluted)-0.39-38.57-299.95-10.09-0.76
Weighted avg. shares (diluted)4.91M609,696172,0317.68M87.89M
Balance sheet
Cash & equivalents$17.27M$6.84M$6.98M$76.66M$110.62M
Current assets$17.59M$8.61M$11.35M$78.85M$111.71M
PP&E, net$0$371,000$3.25M$8.44M$11.05M
Total assets$17.59M$9.31M$17.74M$92.42M$125.17M
Current liabilities$7.91M$12.61M$15.37M$15.11M$10.81M
Total liabilities$8.06M$13.18M$17.62M$46.15M$12.77M
Shareholders' equity$9.53M-$3.87M$123,000$46.27M$112.40M
Shares outstanding————93.58M
Cash flow statement
Operating cash flow-$5.26M-$11.41M-$49.48M-$65.07M-$53.67M
Capital expenditure—$0$64,000$2.71M$3.99M
Free cash flow—-$11.41M-$49.54M-$67.78M-$57.65M
Investing cash flow$1.17M$0$5.89M-$2.95M-$5.37M
Financing cash flow$14.53M$11.27M-$26.08M$34.06M$70.85M
Depreciation & amortization$34,000$671,000$1.86M$2.72M$2.17M
Stock-based compensation$129,000-$450,000$568,000$2.28M$3.31M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.